India Approves Synthetic CBD Oral Solution for Mild to Moderate Anxiety with CBT and Psychiatrist Prescribing
India’s CDSCO approved manufacture and marketing of a synthetic CBD oral solution at 150 mg/mL for mild to moderate anxiety, according to company and pharmaceutical reporting. It is prescribed by psychiatrists alongside cognitive behavioural therapy, with a Phase III trial cited and Phase IV research planned. This product-specific decision should not be generalized to consumer CBD efficacy.
For the full article, please visit the original source link below. CannabisInsight curates and summarizes key news from the global cannabis and hemp industry.
Source
hemptoday.net
CannabisInsight selects and summarizes news from external sources. Copyright in the original articles remains with the respective publishers or institutions. Follow the source links for full reporting and context.
Original Link
https://hemptoday.net/india-clears-synthetic-cbd-anxiety-drug-in-potential-new-market-for-cannabinoid-meds/